abstract |
Anti-MCP-1 / CCR2 antagonist therapies, including, but not limited to, anti-MCP-1 / CCR2 antagonist therapies for the control of profibrous markers associated with fibrotic processes including, but not limited to, collagen matrix deposition and alveolar collapse It is provided for the control or regression of fibrosis related diseases. |